Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | OCGN | Common Stock | Options Exercise | $3.83K | +7.5K | $0.51 | 7.5K | Jul 18, 2022 | Direct | ||
transaction | OCGN | Common Stock | Sale | -$19.3K | -7.5K | -100% | $2.57* | 0 | Jul 18, 2022 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | OCGN | Option (Right to Buy) | Options Exercise | $0 | +7.5K | +500% | $0.00 | 9K | Jul 18, 2022 | Common Stock | 7.5K | $0.51 | Direct | F3 |
Id | Content |
---|---|
F1 | This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. |
F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.56 to $2.61. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
F3 | The options, initially representing a right to purchase 54,000 shares, vest and become exercisable in equal monthly installments over three years commencing on February 2, 2020, subject to continued service with the Company on the applicable vesting dates. |